The seventh warning indicator of poor ovary health or ovarian cancer is a visible change in the bowel movement. Studies have ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...

Ovarian cancer, often diagnosed late due to subtle symptoms, sees significantly improved survival rates with early detection.

World Ovarian Cancer Day is observed every year on May 8 to increase awareness about this dreaded disease, which mostly goes ...

Ovarian cancer, a lethal disease affecting women, accounts for a significant percentage of cancer cases and deaths globally.

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

Ovarian cancer’s lack of early symptoms makes it a difficult disease to catch in its initial stages, but by understanding the ...

MSD has reported that the randomised Phase III KEYNOTE-B96 trial of Keytruda (pembrolizumab) plus chemotherapy (paclitaxel), ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...